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Background: In the USA, human herpesvirus 8 (HHV-8) is associated with Kaposi’s sarcoma (KS) and HIV infection. 
We examined HHV-8 seroprevalence in a Malawian cohort, and assessed its relationship with HIV, KS, demographic 
characteristics, and immune findings. 
Methods: In 1997 and 1998, blood samples were obtained from 272 hospitalized Malawian patients, for whom 
demographic information was obtained, and 24 healthy volunteers without demographic data. We used enzyme 
immunoassays to assess seroprevalence and antibody titers to peptide antigens derived from HHV-8 K8.1 and 
ORF65-encoded proteins. Intracellular cytokines and cell surface antigens were assessed with four-color flow 
cytometry. Data were analyzed using non-parametric univariate and regression analytic techniques. 
Results: The rates of HHV-8 seroprevalence to either or both HHV-8 peptides were 67% for the patients and 54% 
for the healthy volunteers. Seroprevalence increased with patients’ age (P<O.OOl) but was not associated with HIV 
status, percentage of lymphocytes expressing CD4, or KS (n=lO). Seropositive females had lower antibody titers to 
both peptides than did males (medians: 455 versus 1361 for K8.1, P<O.OOl; and 268 versus 405 for ORF65, P=O.O44). 
For the healthy volunteers, the percentage of CD8’ cells producing IFN-7 after stimulation was significantly lower 
in ORF65-specific antibody-positive persons (medians: 24% versus 57%, P=O.OOS). 
Conclusions: In Malawi, HHV-8 is endemic and is not associated with HIV infection or HIV severity. Seroprevalence 
rates increase in childhood, and, most steeply in adolescence. Titers are higher in seropositive males than in sero- 
positive females. The immune effects of HHV-8 in healthy adults are consistent with chronic inhibition of type 1 
cytotoxic T-cell responsiveness, independent of HIV status. 
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INTRODUCTION 
Human herpesvirus 8 (HHV-8) is a recently discovered 
virus. HHV-8 DNA sequences have been found in 
lesions from persons with Kaposi’s sarcoma (KS), sug- 
gesting a causative associati0n.l” In the USA, studies of 
homosexual men have found associations between HHV- 
8 and HIV seropositivity.4 Although HHV-8 is endemic 
in many parts of Africa, previous studies suggest that its 
seroepidemiology varies geographically.5-9 
Despite intense research on HHV-8, many questions 
remain. The data support the sexual transmission of 
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HHV-8; however, it is unclear whether other modes of 
transmission also exist.4,7-12 More information is needed 
concerning HHV-8 seroprevalence in non-homosexual 
populations, variations in HHV-8 seroprevalence by age, 
gender, and country, and the effect of HHV-8, a chronic 
herpesvirus, on the immune system. 
We evaluated the seroprevalence and titers of anti- 
bodies to two HHV-8 antigens in hospitalized patients, 
10 of whom exhibited some form of KS, and 24 employed, 
healthy people in Malawi, Africa. We present results 
concerning: (1) HHV-8 seroprevalence in a non-US 
population where HIV is endemic; (2) age- and gender- 
specific HHV-8 seroprevalence rates; (3) HHV-8 sero- 
prevalence in persons with HIV and/or KS; and (4) for 
the healthy volunteers, relationships between HHV-8 
seropositivity and various immune parameters. 
METHODS 
Participants 
Serum or plasma samples were obtained in 1997 and 
1998 from 272 febrile patients (ages 1 month to 64 
years, median 25 years) hospitalized at Lilongwe Central 
Hospital, Malawi, Africa, as part of a study of blood- 
stream infections.13 Demographic and clinical data were 
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obtained for these patients, but not information con- 
cerning sexual activities or behaviors. Of the 269 patients 
for whom gender was recorded, 53.5% were male. 
To assess associations between HHV-8 serostatus and 
immune findings, HHV-8 serology, HIV serology and 
immune studies were performed on blood drawn from 
24 asymptomatic, apparently healthy, non-hospitalized 
local volunteers, since these persons would not be 
expected to have an acute co-infection. Demographic 
information on these healthy participants was not 
obtained. The study protocol was approved by the in- 
stitutional review boards of the Centers for Disease 
Control and Prevention (CDC) and Lilongwe Central 
Hospital; informed consent was obtained from all parti- 
cipants or their guardians. 
Enzyme immunoassay 
Two enzyme immunoassays (EIAs) using synthetic pep- 
tides derived from the antigens HHV-8 ORF6S4 and 
K8.11s were used to determine HHV-8 seroprevalence, 
and the protocol was followed as previously described.14 
All specimens initially testing HHV-8 positive were 
tested at least once again with each peptide EIA to 
confirm seropositivity. The cutoff for positivity was set at 
five standard deviations above the mean optical density 
(OD) of sera from 18 KS-negative, HIV-negative US 
persons. These sera had previously tested negative for 
HHV-8 with other methods.14 One positive control, an 
HIV-positive US homosexual KS patient who had pre- 
viously tested positive for HHV-8 with other methods, 
was also included on each EIA plate. 
A sample was considered to be HHV-8 positive 
if either or both antibody assays were positive. Using 
this criterion, the assay sensitivity was 93% and the 
specificity was 100% in KS patients and healthy controls 
from the US population. Is Fourfold serial dilutions were 
made of all positive samples. The endpoint titer was 
determined for the positive samples, from plots of OD 
versus dilution, and was taken as the dilution value 
where the titration curve intersected the cutoff value for 
positivity. 
Immune techniques 
Serum samples were analyzed for interleukin (IL)-2, IL- 
4, IL-6, IL-8, IL-lo, interferon-gamma (IFN-y), and 
tumor necrosis factor alpha (TNF-of) by enzyme-linked 
immunosorbent assays (ELISAS) (Becton Dickinson 
Immunocytometry Systems/PharMingen, San Jose, CA, 
USA). Whole blood was stimulated for intracellular 
cytokine production using phorbol 12-myristate 13- 
acetate (PMA)-ionomycin for 5 h at 37”C.16 Four-color 
cytofluorometry was done using a FACSort or FACS 
Calibur flow cytometer and CellQuest software (Becton 
Dickinson Immunocytometry Systems/PharMingen).*6 
Fluorescein isothiocyanate (FITC)-conjugated, phyco- 
erythrin (PE)-conjugated, peridinin chlorophyll protein 
(PerCP)-conjugated or allophycocyanin (APC)-con- 
jug&d murine monoclonal antibodies were obtained 
from the following sources: (1) Becton Dickinson 
Immunocytometry SystemslPharMingen (CD8-FITC 
and CD8-PE (clone SKl), CD3-PerCP and CD3-APC 
(clone SK7), CD4-APC (clone SK3), CD45-FITC 
(clone 2Dl), CD19-APC (clone SJ25Cl), CD14-PE 
(clone MNP9), CD69 (clone L78), CD16-PE (clone 
B73.1), CD56 (clone MY31) , IL-4-PE (clone 8D4-8), 
IL-8-PE (clone G265-8), IL-lo-PE (clone JES3-9D7), 
and IL-12-FITC (clone C11.5)); (2) Research and 
Diagnostics, Minneapolis, MN, USA (IL-6-PE (clone 
1927.311)); (3) Immune Source, Reno, NV, USA 
(CD8-APC ( 1 cone KL.12), IL-2-APC (R-56.2), IL- 
12-FITC (clone l.Al), TNF-(Y-FITC (clone DTX.34), 
and IFN-y-APC (clone 13.TR)); (4) Sigma (St Louis, 
MO, USA) microtubulin (MT) (clone DMlA) custom 
conjugated to FITC by CalTag, South San Francisco, 
CA, USA; and (5) Endogen, Woburn, MA, USA (T-cell 
antigen y6 receptor chains-FITC (clone 5A6.E9)). 
Isotype controls were obtained from Becton Dickinson 
Immunocytometry Systems/PharMingen. All antibodies 
used had been pretested for stability to the 
permeabilization-fixation protocol. 
Statistical analyses 
Fisher’s exact tests or chi-square analyses were per- 
formed for comparison of categorical variables, in- 
cluding age group (defined as < 13 years old versus 2 13 
years old), gender, blood culture status, HIV status, 
HHV-8 status, and presence/absence of acute or chronic 
symptomatology (cough, fever, diarrhea, etc.). Of these 
categorical variables, only HIV and HHV-8 status were 
available for the healthy, working volunteers, none of 
whom were acutely or chronically ill by self-report. 
Continuous variables of seropositive and seronegative 
participants were compared with Wilcoxon signed-rank 
tests. Logistic regression analyses were done to deter- 
mine which demographic or, for the healthy volunteers, 
which immunologic parameters were independently 
associated with HHV-8 seropositivity. Linear regression 
analyses were done to determine which continuous 
variables were associated with HHV-8 antibody titers. 
The significance level for all tests was set at P=O.O5; 
however, in logistic regression analyses, levels of retained 
significance were much higher than this level, ruling 
against them being an artifact of multiple comparisons. 
RESULTS 
HHV-8 seroprevalence 
The seroprevalence rate of patients for ORF65 was 
54%, and that for Kg.1 was 61%, resulting in an overall 
HHV-8 seroprevalence rate of 67% for hospitalized 
patients. The HHV-8 seroprevalence rate for healthy 
volunteers was 54%. Seroprevalence rates did not differ 
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significantly between patients and healthy volunteers 
(67% versus 54%) or between male and female patients 
(65% versus 70%). Seroprevalence rates did vary signi- 
ficantly by patients’ age group (children, defined as < 13 
years old=28% versus adults, defined as 213 years 
old=75%) (P<O.OOl) and by actual age in years (Figure 
1). The patterns were similar for both antigens (Figure 
1). The ages of the seven seropositive children were 0.1, 
1.2,2,4,9,10 and 12 years. Four were male and two were 
HIV seropositive. 
HHV-8 seroprevalence was not associated with 
the severity of HIV infection, as represented by the 
percentage of lymphocytes expressing CD4, or with the 
presence or absence of malaria parasitemia (Table 1). 
HHV-8 positivity was also not associated with a chronic 
cough, chronic vomiting, or diarrhea, or the number of 
people living in a household. 
In univariate analyses, HHV-8 seropositivity was 
significantly associated with HIV seropositivity in the 
patients. However, in a logistic regression analysis in- 
cluding HIV status, age, and the percentage of lympho- 
cytes expressing CD4 as independent variables, HHV-8 
seropositivity was not significantly associated with HIV 
or the percentage of lymphocytes expressing CD4 when 
age was taken into account. HHV-8 seropositivity 
remained highly associated with age (P<O.OOl, p=O.O66, 
95% c1=0.045,0.089). 
HHV-8 antibody titers 
The titers for both peptides increased among patients 
through adolescence into adulthood (Figure 2). Females 
had significantly lower antibody titers than did males 
for both peptides (medians 455 versus 1361 for K8.1, 
P<O.OOl; and medians 268 versus 405 for ORF65, P= 
0.044). 
80 
HHV-8 and KS 
Ten patients had KS lesions on hospital admission 
physical examination (four with skin lesions, three with 
oral lesions, and three with both). Eight of 10 patients 
with KS were HHV-8 positive, and 65% of those with- 
out KS were HHV-8 negative (not significant). 
Relationship between HHV-8 seropositivity and 
immune parameters 
These analyses were done for only the healthy volun- 
teers, to avoid confounding due to acute illness. Several 
immune parameters (see Methods) were examined in 
univariate analyses of data from the 24 healthy, non- 
hospitalized participants. Those that appeared to be 
related to HHV-8 seropositivity were: the percentage of 
CD3+, CD3+/CD8- and CD3+/CD8+ lymphocytes pro- 
Table 1. Characteristics of HHV-8 antibody-positive and 
-negative patients and healthy volunteers 
HHV-8+ HHV-8- P-value 
Patients 
% Male 52 57 NS 
% HIV+ 62 40 0.011 
% Malaria smear positive 13 12 NS 
Age (median) 30 20 <O.OOl 
% of lymphocytes 
expressing CD4 
HIV- participants 29 32 NS 
HIV+ participants 8 9 NS 
Healthy volunteers 
% HIV+ 62 55 NS 
% of lymphocytes 
expressing CD4 
HIV participants 43 42 NS 
HIV+ participants 34 39 NS 
NS, not significant. 
I 
, 
<2 2-4.9 5-14 15-19 20-24 25-29 30-34 35-39 40-49 >=50 
Age Group 
wK8.1 peptide * ORF65 peptide 
Figure 1. HHV-8 seroprevalence, by age group, among hospitalized patients in Malawi, Africa. Symbols represent median values for 
all participants within that age group. Numbers of patients in each age group by year were as follows: ~2, n=20; 2-4.9, n=21; 5-14, 
n=12; 15-19, n=18; 20-24, n= 47; 25-29, n=32; 30-34, n=43; 35-39, n=30; 40-49, n=37; >50, n=8. 
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<I .2 1.2-4.9 5-14 15-19 20-24 25-29 30-34 35-39 40-49 >=50 
Age Group 
Figure 2. HHV-8 antibody titer, by age group, among hospitalized patients in Malawi, Africa. Symbols represent median values for 
all participants within that age group. Numbers of patients in each age group who were seropositive for K8.1 peptide and ORF65 
peptide respectively were: ~1.2, n =l, 0; 1.2-4.9, n=5, 5; 5-14, n=4, 2; 15-19, n=13, 9; 20-24, n= 31, 29; 25-29, n=24, 21; 30-34, 
n=29, 28; 35-39, n=22, 20; 40-49, n=28, 27; >50, n=8,7. 
ducing TNF-(-w with stimulation, the percentage of mono- 
cytes spontaneously producing IL-& and the percentage 
of CD3+/CD8+ lymphocytes producing IFN-y with 
stimulation. However, in a series of logistic regression 
analyses, only the percentage of CD8’ lymphocytes pro- 
ducing IFN-7 with stimulation remained significantly- 
and strongly-related to K&l-specific antibody positivity 
% 
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Figure 3. Percentage of CD8+ ceils producing IFN-?/ with 
stimulation, by HHV-8 status and peptide serology. Boxes 
include medians (lines) and values between the 25th and 75th 
percentiles for the following participant groups: anti-K8.1 
antibody positive (n=13); anti-K8.1 antibody -negative (n= 11); 
anti-ORF65 antibody positive (n=8); and anti-ORF65 antibody 
negative (n= 16). Lines extend to the farthest value within -+ 1.5 
times the interquartile range from the 25th and 75th 
percentiles. 
(P=O.O08, p= -0.107,95% CI= -0.206, -0.041) (Figure 
3). HIV status and the percentage of lymphocytes ex- 
pressing CD4 were not significant in these analyses. A 
similar trend was found for anti-ORF65 peptide posi- 
tivity, although this did not reach statistical significance. 
DISCUSSION 
HHV-8 infection occurs relatively infrequently in US, 
European, and Japanese pediatric and heterosexual 
populations. 17-22 In Cameroon, HHV-8 DNA sequences 
were reported to be present in 62% of healthy adults 
(aged 30-40 years), 52% of adolescents (aged 15-20 
years), and 40% of healthy children (aged 5-10 years).7 
This suggests that HHV-8 is endemic to Cameroon, with 
many infections occurring in preadolescence. However, 
this age distribution is very different from that found in 
US and European studies. A low rate of HHV-8 sero- 
positivity was found in HIV-infected US children (aged 
0.5-18 years) enrolled in HIV clinical trials, supporting 
the suggestion that, in the USA, primary HHV-8 infection 
occurs in adulthood.*i Similarly, HHV-8 seropositivity 
was unusual in the children in our cohort. In our study, 
HHV-8 seropositivity rates increased most precipitously 
among patients between 15 and 19 years of age, in- 
dicating that primary infection in Malawi usually occurs 
during adolescence. 
Non-sexual modes of viral transmission comprise 
intrauterine, perinatal, aerosol, fecal-oral, casual contact 
and vectors. We did not study specific modes of trans- 
mission; however, our results concerning HHV-8 age 
distribution and the lack of association of HHV-8 sero- 
positivity with malaria, respiratory symptoms, gastro- 
intestinal symptoms and the number of household 
members suggest that the above-mentioned possibilities 
are uncommon modes of HHV-8 transmission in Malawi. 
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Of the 20 children less than 2 years of age in our study, 
two were HHV-8 seropositive (aged 0.1 and 2 years); 
this is consistent with either mother-child transmission, 
or placental transfer of maternal antibody. Reports of 
intrauterine or perinatal HHV-8 transmission are largely 
anecdota1.l’ In one cohort study, no infants of 17 HHV- 
8-seropositive mothers were infected with the virus.‘* In 
our study, seropositivity in childhood was less common 
than in studies done in Cameroon7 and Uganda;8 only 
5 of 29 Malawian children 2-12 years of age were HHV- 
8 seropositive. Varying cultural practices, (e.g. sharing 
or non-sharing of eating utensils), as well as varying 
rates of viral endemicity in adults, may play a role in the 
different seroprevalence rates among these three African 
pediatric populations. 
Both HIV and HHV-8 appear to be endemic in 
Malawi; however, contrary to findings for US homo- 
sexual cohorts, we found no independent association 
between HHV-8 and HIV seropositivity when we con- 
trolled for age. For healthy volunteers, all of whom were 
employed adults, HIV status did not differ significantly 
between the HHV-8-positive and HHV-8-seronegative 
participants. This result is consistent with findings in 
South Africa.9 
Moore et al observed that HHV-8 antibody titers 
are significantly higher among HIV-positive/KS-positive 
patients than among HIV-negative/KS-negative US 
control patients. 23 High titers of HHV-8 antibodies 
among patients in South Africa have been associated 
with KS.9 In our study, 8 of 10 KS patients tested positive 
for lytic HHV-8 antibodies, compared to 65% of patients 
without KS. Although HHV-8 seroprevalence and 
antibody titers did not differ significantly between KS 
and non-KS patients in our cohort, the number of KS 
patients in our study was small, and thus the power of 
our analysis was low. 
Two of our findings appear not to have been 
previously reported. First, we found that HHV-8 
antibody titers were related to gender, with females 
having lower titers of antibodies to both antigens. To our 
knowledge, our study is the first to report gender-specific 
differences in HHV-8 antibody titers. Second, we found 
that the percentage of CD8 cells producing IFN-y after 
stimulation with PMA and ionomycin was lower in 
healthy persons with HHV-8 infection, irrespective of 
their HIV status or proportion of lymphocytes express- 
ing CD4. This immune finding suggests that HHV-8 
infection may be associated with inhibition of type 1 
cytokine production by cytotoxic T cells, irrespective of 
any effects of potential coexistent HIV infection. This 
would be consistent with the proposed importance of 
CD8 cells and IFN-y in maintaining the chronicity of 
HHV-8 infection.24 
In summary, we found HHV-8 to be endemic in 
Malawi, with primary transmission usually occurring in 
adolescence. Antibody titers were lower in seropositive 
females. Seropositivity was unrelated to HIV, and its 
relationship with KS could not be confirmed, perhaps 
because of the small number of KS patients. The immune 
effects of HHV-8 are consistent with chronic infection 
and suppressed type 1 cytokine production by CDS+ T 
cells. 
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